MMT-205 simultaneously activates Tie2 and inhibits VEGF, targeting two clinically validated pathways implicated in retinal and vascular disease.
Preclinical data indicate greater Tie2 activation and improved retinal vasculature integrity compared with anti-VEGF monotherapies, supported by a licensing deal with upfront cash, equity, and milestone payments.
Neovascular age-related macular degeneration and diabetic macular edema represent major causes of vision loss, with anti-VEGF therapies established as standard of care.
MMT-205's dual mechanism of Tie2 activation plus VEGF inhibition is positioned to improve upon existing monotherapies by addressing vascular instability alongside neovascularization.
Memento Medicines' lead program is MMT-205, a potential best-in-class bispecific antibody that activates Tie2 signaling while inhibiting VEGF.
The therapy is in development for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), with IND-enabling studies underway and clinical trials expected to begin in 2027.
